Wang C - Search Results

1

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.

Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, Yang Q, Liu W, Wang Y, Wu Z, Han W. Tong C, et al. Among authors: wang y, wang c. Blood. 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278. Blood. 2020. PMID: 32556247 Free PMC article. Clinical Trial.

2

An LRP16-containing preassembly complex contributes to NF-κB activation induced by DNA double-strand breaks.

Wu Z, Wang C, Bai M, Li X, Mei Q, Li X, Wang Y, Fu X, Luo G, Han W. Wu Z, et al. Among authors: wang y, wang c. Nucleic Acids Res. 2015 Mar 31;43(6):3167-79. doi: 10.1093/nar/gkv161. Epub 2015 Mar 3. Nucleic Acids Res. 2015. PMID: 25735744 Free PMC article.

3

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.

Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, Wang Y, Wang C, Shi F, Zhang Y, Chen M, Feng K, Wang Q, Zhu H, Fu X, Li S, Han W. Dai H, et al. Among authors: wang y, wang c, wang q. Oncoimmunology. 2015 May 26;4(11):e1027469. doi: 10.1080/2162402X.2015.1027469. eCollection 2015 Nov. Oncoimmunology. 2015. PMID: 26451310 Free PMC article.

4

An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.

Zhang Y, Zhang W, Dai H, Wang Y, Shi F, Wang C, Guo Y, Liu Y, Chen M, Feng K, Zhang Y, Liu C, Yang Q, Li S, Han W. Zhang Y, et al. Among authors: wang y, wang c. Sci China Life Sci. 2016 Apr;59(4):379-85. doi: 10.1007/s11427-016-5035-4. Epub 2016 Mar 24. Sci China Life Sci. 2016. PMID: 27009300

5

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, Li X, Zhang YJ, Zhang WY, Chen MX, Zhang Y, Feng KC, Liu Y, Li SX, Yang QM, Han WD. Wang CM, et al. Clin Cancer Res. 2017 Mar 1;23(5):1156-1166. doi: 10.1158/1078-0432.CCR-16-1365. Epub 2016 Aug 31. Clin Cancer Res. 2017. PMID: 27582488 Clinical Trial.

6

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.

Zhang WY, Wang Y, Guo YL, Dai HR, Yang QM, Zhang YJ, Zhang Y, Chen MX, Wang CM, Feng KC, Li SX, Liu Y, Shi FX, Luo C, Han WD. Zhang WY, et al. Among authors: wang y, wang cm. Signal Transduct Target Ther. 2016 Mar 11;1:16002. doi: 10.1038/sigtrans.2016.2. eCollection 2016. Signal Transduct Target Ther. 2016. PMID: 29263894 Free PMC article.

7

Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials.

Zhang WY, Liu Y, Wang Y, Wang CM, Yang QM, Zhu HL, Han WD. Zhang WY, et al. Signal Transduct Target Ther. 2017 Oct 9;2:17054. doi: 10.1038/sigtrans.2017.54. eCollection 2017. Signal Transduct Target Ther. 2017. PMID: 29263931 Free PMC article. No abstract available.

8

Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy.

Zhang WY, Liu Y, Wang Y, Nie J, Guo YL, Wang CM, Dai HR, Yang QM, Wu ZQ, Han WD. Zhang WY, et al. Gene Ther. 2018 Jun;25(3):198-204. doi: 10.1038/s41434-017-0001-8. Epub 2018 Mar 29. Gene Ther. 2018. PMID: 29599530

9

Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, Li X, Liu J, Ku W, Zhang Y, Chen M, An X, Shi L, Brock MV, Bai J, Han W. Nie J, et al. Among authors: wang c. J Clin Oncol. 2019 Jun 10;37(17):1479-1489. doi: 10.1200/JCO.18.02151. Epub 2019 Apr 30. J Clin Oncol. 2019. PMID: 31039052 Clinical Trial.

10

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.

Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, Zhang Y, Chen M, Yang Q, Wang Y, Han W. Dai H, et al. Among authors: wang y, wang c. J Hematol Oncol. 2020 Apr 3;13(1):30. doi: 10.1186/s13045-020-00856-8. J Hematol Oncol. 2020. PMID: 32245502 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

101,603 results

Search Page